U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07439055) titled 'Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A' on Jan. 20.
Brief Summary: Recent studies have shown that pharmacokinetic (PK)-guided extended half-life (EHL) factor VIII can improve joint health in patients with hemophilia A. However, some patients experience suboptimal joint outcomes despite optimized PK-guided therapy. Low-dose emicizumab has emerged as a potential option for improving bleeding control and joint health in patients who do not respond adequately to PK-guided EHL factor VIII.
The objectives of the study is to compare clinical bleeding outcomes, joint health, ca...